admin@ads4.us

Medications are often used off label when they are found to have properties or effects that could potentially benefit a disease state or condition they were not originally intended for. Up to one-third of all prescriptions for common medications in the United States are used off label.1 Glucagon-like peptide 1 (GLP-1) receptor agonists are a […]

GLP-1 is an incretin hormone that is released from the distal ileum in the small intestine and the colon within minutes of ingesting food. It has been shown to decrease glucagon secretion, increase glucose uptake and glycogen synthesis in the peripheral tissues, delay gastric emptying, and increase satiety.4 GLP-1 was first discovered in 1987 by

Originally developed to improve glycaemic control in patients with type 2 diabetes, GLP-1 receptor agonists have emerged as promising agents for weight management and cardiovascular protection, expanding their therapeutic potential beyond diabetes care.1 Since 2016, clinical trials such as LEADER,2 SELECT,3 and SURPASS4 have demonstrated the cardiovascular benefits of GLP-1 receptor agonists, consistently showing a

Along with helping to control blood sugar and boosting weight loss, GLP-1 agonists and SGLT-2 inhibitors seem to have other health benefits. Research has found that some of these medicines may lower the risk of certain serious health conditions, such as kidney disease, heart disease, heart failure and stroke. Many people who take these medicines

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects. Muscle loss is a big concern for people on anti-obesity medications such as semaglutide. These ‘GLP-1 agonists’ mimic a natural gut hormone — glucagon-like peptide 1 — to suppress appetite and regulate metabolism. But

Researchers are currently studying the safety and effectiveness of GLP-1 agonists for people with Type 1 diabetes (T1D). So far, some studies show that these medications can help lower A1C and help with weight loss in people with T1D. The FDA hasn’t approved GLP-1 agonists for the treatment of T1D. But some healthcare providers prescribe

ABSTRACT: Myocardial infarction (MI) continues to be a leading cause of death in the United States. Improvements in the diagnosis and treatment of acute MI have reduced in-hospital mortality from 30% in the 1970s to about 5% currently. The traditional functions of hospital pharmacists in MI care involve patient education and counseling on risk-factor modification

ABSTRACT: Telehealth has gained significant traction in recent years, enabling healthcare providers, including pharmacists, to enhance continuity of care. Findings indicate that technology-based interventions and monitoring can improve outcomes such as time within the therapeutic range and adherence while reducing adverse events such as thromboembolic incidents or bleeding. Emerging technologies, including artificial intelligence, personal coagulometers,

ABSTRACT: Cardiovascular disease (CVD) is the leading cause of death globally, with costs expected to increase drastically over the next few decades. Health coaching has emerged as a potential adjunct treatment option for addressing CVD risk factors. Several studies show the positive impacts of health coaching on CVD risk factors. Health coaching, however, is an

Trouble Digesting Sugar in Milk Lactose, a natural sugar found in milk and products made from milk, is digested in the body by an enzyme known as lactase. If a person does not produce sufficient lactase, lactose can be difficult to digest. In some people, this problem results in a condition known as lactose intolerance.